Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Buy” from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given an average rating of “Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $42.83.

A number of analysts recently issued reports on DNTH shares. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating on the stock. Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Wedbush increased their price objective on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, May 10th. HC Wainwright initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, May 16th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Raymond James increased their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a report on Thursday, April 18th.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Octagon Capital Advisors LP lifted its stake in shares of Dianthus Therapeutics by 15.4% in the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after buying an additional 74,000 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $1,404,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics in the third quarter worth about $53,000. Hussman Strategic Advisors Inc. acquired a new stake in Dianthus Therapeutics during the first quarter worth about $630,000. Finally, Vanguard Group Inc. increased its position in Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $28.61 on Friday. The company’s fifty day moving average price is $24.49 and its 200 day moving average price is $22.60. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The company has a market capitalization of $839.70 million, a PE ratio of -4.91 and a beta of 1.89.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The company had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. On average, equities analysts expect that Dianthus Therapeutics will post -2.18 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.